Duration of response to first androgen deprivation therapy, time to castration resistance prostate cancer, and outcome of metastatic castration resistance prostate cancer patients treated with abiraterone acetate
作者: Silvana GiacintiPaolo CarliniMichela RobertoMaria BassanelliLidia StrigariFrancesco PaveseAnna M. AschelterAlessandra FeliciMaurizio ValerianiFrancesco CognettiPaolo Marchetti
作者单位: 1aDepartment of Clinical and Molecular Medicine, University Sapienza of Rome bDepartment of Radiation Oncology, Sant’Andrea Hospital Departments of cMedical Oncology dMedical Physics and Expert Systems, Regina Elena National Cancer Institute, Rome, Italy
刊名: Anti-Cancer Drugs, 2016
来源数据库: Wolters Kluwer Journal
DOI: 10.1097/CAD.0000000000000434
原始语种摘要: Abiraterone acetate (AA) demonstrated its efficacy in the treatment of patients with metastatic castration resistance prostate cancer (mCRPC) in predocetaxel and postdocetaxel setting. However, we learn from pivotal studies that forms of primary and acquired resistance to this drug exist. Patient selection becomes so crucial to optimize treatment results. Potential predictive biomarkers have been identified but are not yet validated. In this scenario, clinical features and disease characteristics may still be of value in selecting patients for different treatments. The objective of this retrospective study was to assess whether or not a correlation between duration of response to first androgen deprivation therapy (ADT), time to castration-resistant prostate cancer (TTCRPC), and outcome...
全文获取路径: Wolters Kluwer 
影响因子:2.232 (2012)

  • 生存 新陈代谢的
  • castration 去雄
  • androgen 雄激素
  • prostate 前列腺
  • acetate 醋酸盐
  • deprivation 丧失
  • outcome 效果
  • treated 加工的
  • metastatic 新陈代谢的
  • survival 新陈代谢的
  • response 响应